Substance use disorder treatment has historically relied on a combination of counseling, peer support, and in some cases medication-assisted treatment — with treatment retention remaining one of the most stubborn challenges in the field. A category of FDA-authorized digital therapeutics has emerged specifically targeting that retention problem, built around a behavioral principle with decades of research support: contingency management.
The Contingency Management Foundation
Contingency management is a behavioral intervention that provides tangible incentives — often modest financial rewards or vouchers — for verified drug-negative test results or other treatment-adherent behaviors. Despite being one of the most extensively researched behavioral interventions in addiction medicine, with a substantial body of clinical trial evidence supporting its effectiveness, contingency management has historically been underused in traditional treatment settings due to the administrative burden of managing verification and reward logistics.
Digital therapeutics built on this model automate that logistics problem: patients submit required check-ins or connect verified testing devices, the app tracks adherence, and rewards are distributed automatically according to a pre-set schedule — removing the administrative burden that limited contingency management's real-world adoption despite strong trial evidence.
What FDA-Authorized Programs Have Shown
Several digital therapeutics targeting substance use disorder have received FDA marketing authorization based on randomized controlled trial evidence showing improved treatment retention and increased periods of abstinence compared to standard treatment alone. These programs are typically authorized as an adjunct to, not a replacement for, a broader outpatient treatment program that includes counseling and, where clinically appropriate, medication-assisted treatment such as buprenorphine or naltrexone.
Addressing the Isolation Factor
Beyond contingency management mechanics, several programs incorporate cognitive behavioral therapy content, craving and trigger management tools, and in some cases connect patients with peer recovery support — recognizing that substance use disorder treatment engagement often falters between scheduled counseling sessions, precisely the gap where relapse risk concentrates. A 24/7 available tool that a patient can open during a craving episode, rather than waiting for a weekly appointment, addresses a real structural gap in traditional outpatient treatment models.
Integration With Medication-Assisted Treatment
A growing number of programs are being deployed specifically alongside medication-assisted treatment for opioid use disorder, an area where treatment retention strongly predicts long-term outcomes and where the consequences of early dropout can be fatal given overdose risk during and after treatment gaps. Digital tools that improve visibility into early disengagement — allowing a care team to reach out proactively rather than discovering a missed appointment after the fact — represent a meaningful clinical safety mechanism, not just a convenience feature.
Access and Reimbursement
As with other digital therapeutics, reimbursement remains uneven across payers, though substance use disorder treatment has benefited from broader policy momentum around addressing the opioid crisis, including some state Medicaid programs specifically adding coverage for digital SUD treatment tools as part of broader opioid response funding.
Conclusion
Digital therapeutics for substance use disorder bring a well-established but historically underused behavioral intervention — contingency management — to a scale and consistency that traditional treatment infrastructure has struggled to deliver. Used as an adjunct within a broader treatment program, the early evidence suggests real potential to improve the retention outcomes that so often determine whether treatment succeeds.
